Program Information
Dosimetric Impact of Breast Contour Reconstruction Errors in GammaPod Stereotactic Radiotherapy
Y Niu1*, S Becker2 , C Yu1,2 , Y Mutaf2 , (1) Xcision Medical Systems LLC, Columbia, MD, (2) University Maryland School of Medicine, Baltimore, MD,
Presentations
SU-C-BRB-6 (Sunday, July 31, 2016) 1:00 PM - 1:55 PM Room: Ballroom B
Purpose: The first GammaPod™ unit, a dedicated prone stereotactic treatment device for early stage breast cancer, has been installed and commissioned at University of Maryland School of Medicine. The objective of this study was to investigate potential dosimetric impact of inaccurate breast contour.
Methods: In GammaPod treatments, patient’s beast is immobilized by a breast cup device (BCID) throughout the entire same-day imaging and treatment procedure. 28 different BICD sizes are available to accommodate patients with varying breast sizes. A mild suction helps breast tissue to conform to the shape of the cup with selected size. In treatment planning, dose calculation utilizes previously calculated dose distributions for available cup geometry rather than the breast shape from CT image. Patient CT images with breast cups indicate minor geometric discrepancy between the matched shape of the cup and the breast contour, i.e., the contour size is larger or smaller. In order to investigate the dosimetric impact of these discrepancies, we simulated such discrepancies and re-assessed the dose to target as well as skin.
Results: In vicinity of skin, hot/cold spots were found when matched cup size was smaller/larger than patient’s breast after comparing the corrected dose profiles from Monte Carlo simulation with the planned dose from TPS. The overdosing/underdosing of target could yield point dose differences as large as 5% due to these setup errors (D95 changes within 2.5%). Maximal skin dose was overestimated/underestimated up to 25%/45% when matched cup size was larger/smaller than real breast contour.
Conclusion: The dosimetric evaluation suggests substantial underdosing/overdosing with inaccurate cup geometry during planning, which is acceptable for current clinical trial. Further studies are needed to evaluate such impact to treating small volume close to skin.
Contact Email: